Earnings call transcript: Harmony Biosciences Q1 2026 misses EPS forecast By Investing.com

Harmony Biosciences reported Q1 2026 EPS of $0.55 versus $0.76 expected and revenue of $215.4 million versus $228.4 million expected, triggering a 10.77% pre-market drop to $29.25. Despite the miss, revenue rose 17% year over year and the company reaffirmed full-year revenue guidance of $1.0 billion to $1.04 billion. Investors are also weighing rising operating expenses from licensing fees, ongoing patent litigation around WAKIX, and the company’s pipeline progress, including BP-205 and pitolisant GR.

Analysis

The selloff looks less like a one-quarter earnings issue and more like the market repricing the quality of Harmony’s “self-funding” story. The mix shift toward licensing and royalties means every incremental dollar of growth now carries more friction, so upside from WAKIX volume is increasingly capped by higher gross-to-net and upfront R&D absorption. That matters because the stock has been valued as a cash generative, low-burn biotech; once the market starts capitalizing near-term margin compression instead of pipeline optionality, the multiple can compress faster than the EPS miss alone would imply.

The second-order dynamic is that management is effectively asking investors to underwrite a long-duration litigation and lifecycle-management bundle while the core asset is still doing the heavy lifting. If the IP posture holds, the downside is limited to higher legal and launch expense; if it weakens, the valuation support from exclusivity collapses just as generic timing becomes more relevant. Meanwhile, the new formulation and orexin program create a real strategic fork: the company can either protect the cash engine or redeploy capital into adjacent CNS assets, but doing both aggressively raises execution risk and can keep operating leverage suppressed for several quarters.

Consensus is likely underestimating how much of the negative move is already discounting the bad quarter, not the strategic upside. The counterpoint is that the balance sheet gives them time, and the guidance hold suggests underlying demand is not broken; if patient growth re-accelerates into mid-year and BP-205 clears its next PK hurdle, the stock can recover sharply because positioning is likely crowded to the downside. The real catalyst window is 1-2 quarters, while litigation resolution and franchise extension are a 6-18 month path; those are different timers, and the market is treating them as one.

Key Decisions for Investors

• Buy HRMY only on a post-gap stabilization close above the 50-day moving average; risk/reward improves if the market stops pricing an earnings-quality reset and starts focusing on cash generation and IP durability.
• Pair trade: long HRMY / short a higher-beta CNS or small-cap biotech basket for 2-3 months; thesis is that Harmony’s balance sheet and near-term cash flow should outperform speculative names if risk appetite fades.
• Avoid chasing the dip until the next patient-add print; if WAKIX growth re-accelerates next quarter, upside re-rating could be 15-20%, but another access-related deceleration would keep the multiple under pressure.
• For event-driven accounts, consider a defined-risk HRMY call spread dated to the next BP-205 data window; the upside is a sentiment reset on pipeline validation, while the premium is capped if litigation headlines dominate.
• If already long, hedge with short-dated put protection into the next legal milestone; litigation headlines can move the stock more than fundamentals over days, even if the medium-term IP thesis remains intact.